$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Cellular proteins play a pivotal role in orchestrating the complex biological processes that occur within living organisms. The optimal functioning of these pathways is dependent on the interplay between proteins and other biomolecules inside the cell, including interactions with partner proteins and nucleic acids1. Thus, comprehending the intricacies of cellular processes necessitates a deep understanding of the dynamics of protein-nucleic acid interactions.
Traditionally, protein-nucleic acid interactions have been studied using electrophoretic mobility gel shift assays (EMSAs)2. In this assay, proteins are incubated with synthetic oligonucleotides (either DNA/RNA, containing specific lengths or sequences) for a short period, and the reaction is then electrophoresed on a native polyacrylamide (PAGE) gel3,4,5. To enable visualization of the protein-oligonucleotide interaction, the oligonucleotides are typically radioactively labeled with 32P or tagged with fluorescent molecules. If the protein interacts and binds the oligonucleotide, then the binding of the protein slows down the mobility of the nucleic acid within the gel6,7. Thus, this method is also called the gel shift or gel retardation assay. Though this method has been extensively used, there are a few limitations to consider while using this method to obtain KD values, including low resolution from either weak or dynamic binding, the requirement for a significantly high concentration of proteins, and more effort. Additionally, EMSAs are not real-time assays and, therefore, cannot accurately measure binding kinetics7,8.
Innovative techniques such as surface plasmon resonance (SPR) and biolayer interferometry (BLI) have emerged to overcome these limitations9,10,11,12. Both methods measure association/dissociation rate constants and affinity constants between molecules in a label-free manner. Since the protein is not required to be tagged, these techniques eliminate the risk of altering the properties of the protein or blocking the binding site. In SPR, polarized light interacts with a sensor (a metal conducting film, typically gold), generating an electron charge density wave called plasmon. This interaction diminishes the reflected beam's intensity and a detector measures the change in the specific angle, known as the resonance angle13. To study ligand (nucleic acid) - analyte (protein) interactions, the ligand is immobilized in one flow cell on the sensor chip, and the analyte is injected into the flow cell containing the immobilized ligand. On binding the analyte to the ligand, there is a detectable change in the refractive index near the sensor surface, thus allowing for the measurement of molecular interactions14,15,16.
Bio-Layer Interferometry (BLI) measures the pattern of light interference as light passes through an optical fiber with a biolayer, composed of a ligand (bait) and its binding partner (analyte), at the bottom surface of biosensor's tip. Light is transmitted through the tip and reflected at both ends of the biolayer due to the biolayer's properties. The biolayer thickness is proportional to the number of bound molecules that influence the pattern of the reflected light. By comparing the change of the curve of relative intensity vs. wavelength caused by interference between the reflected light from the reference interface and from the biolayer/buffer interface, the thickness change of the biolayer can be determined. When more molecule binds, a greater shift occurs, making BLI a powerful tool for studying biomolecular interactions in real time. The change in the interference pattern is measured and represented on a sensorgram as a spectral shift17,18 (Figure 1A). The nature of the binding interaction can be accurately determined by using appropriate controls, such as a setup lacking the ligand-varying concentrations of the binding partner19,20,21. Compared to SPR, BLI is cost-effective and user-friendly, rendering it accessible to a broad range of researchers. Additionally, samples used in BLI remain intact if there is no degradation or aggregation. This allows them to be possibly recovered and reused, thereby minimizing waste. The BLI instrument operates without the use of microfluidics, thereby eliminating the disadvantages of the fluidics system, such as the need for maintenance/care, clogging, or use of degassed buffers. It also minimizes the risk of contaminating the instrument due to unfiltered or crude protein samples.
In a BLI experiment, the biolayer is established by immobilizing the bait molecule on the biosensor. The biolayer of biosensors can interact with various tags, making it possible to study the interactions between molecules (including nucleic acids, proteins, antibodies, viruses, small molecules, etc.)22. Various capturing strategies, including biotin/streptavidin, 6X-His-tag/Ni-NTA, FLAG/anti-FLAG, GST/anti-GST, and antibody/anti-Fc, can be employed to establish this immobilization. Maintaining the structure and activity of the immobilized ligand is crucial when choosing the biosensor. The changes in the interference pattern are influenced by the amount of bound molecule as well as the matrix23. Protein-nucleic acid interactions are studied using biotinylated oligonucleotide probes that can be immobilized on streptavidin-coated biosensors. Protein samples expected to interact with the immobilized bait (oligonucleotide) are in contact with the oligonucleotide for a specific period in a binding buffer to measure association and subsequently switched to a blank binding buffer to measure dissociation. A schematic representation of analyte binding and corresponding changes in the binding curve is shown in Figure 1B. Additionally, protein-nucleic interactions can also be studied by a reversed immobilization route, in which the protein (bait) is captured on the biosensor and interacts with the nucleic acid (analyte).
Currently, multiple instruments are available commercially that operate on the principle of biolayer interferometry. A straightforward and cost-effective instrument is known as the Octet N1 system, which features a single channel for data throughput. It requires manual operation, consumes minimal sample volume (4 µL), and performs sample analysis at ambient temperatures9,23. This single-channel instrument can detect binding efficiencies of proteins larger than 10 kDa and measures affinities in the micromolar (µM) to nanomolar (nM) range11,12. Some instruments with 2, 8, 16, and 96 channels for automated data reading are also available and compatible with both 96 or 384 well formats19,20. Some of these instruments can also operate between 4 °C to 40 °C, detect biomolecules with molecular weight as low as 150 Da, and measure affinities within the millimolar to picomolar range19,21. While the described system is cost-effective, the pricier instruments with multiple channels offer high-throughput automatic processing. These advanced systems are commonly employed in characterizing and developing biological drug molecules9,23.
The current protocol describes the steps involved in measuring the binding parameters of replication protein A (RPA) to single-stranded DNA (ss-DNA) using the single-channel, manual biolayer interferometry system. RPA is a heterotrimeric, ssDNA-binding protein complex that plays a critical role in almost all aspects of DNA metabolism, including DNA replication, repair, and recombination24. Due to its high affinity to ssDNA (measured to be in the sub-nanomolar range), it can rapidly bind to ssDNA generated during various DNA transactions, protect it from nucleolytic degradation, and prevent impromptu binding of other downstream proteins. RPA also plays a critical role in preventing the formation of non-canonical secondary and tertiary structures, such as G-quadruplexes25. Human RPA is made up of three subunits: RPA70 (70 kDa), RPA32 (32 kDa), and RPA14 (14 kDa), also called RPA 1, RPA 2, and RPA 3, respectively24,26,27. These subunits house six oligonucleotide/oligosaccharide binding folds (OB-folds) labeled A to F. Among these, the DNA binding domains (DBDs) are on the RPA1 (DBD-A, DBD-B, DBD-C) and RPA2 (DBD-D) subunits28. It was first thought that depending on the DNA's length, RPA exhibits different binding modes where different DBDs were engaged to specific DNA lengths29. Data from recent structural and single molecule studies have helped refine these models to suggest that the binding of different DBDs of RPA is more dynamic than initially suggested30,31,32,33,34,35,36. This feature of the dynamic binding property is essential to the function of RPA because RPA should be able to bind tightly to the DNA substrate during certain DNA transactions; however, it should also be able to displace from the substrate to hand over the substrate to the next protein during the biological process. Using different biochemical techniques, the KD for RPA has been determined to be about 0.4 nM for a ss-(polydT)30 substrate, and 80 nM and 200 nM for ss-(polydA)257 and dG-(polydG)602 substrates respectively, as measured by fluorescence polarization anisotropy (FPA)37,38. RPA also shows about a 50-fold higher preference for binding to pyrimidine rich sequences compared to purines. Though different biochemical techniques have determined differing KD measurements for RPA, all measurements have been in the nanomolar range, suggesting RPA's high binding affinity for ssDNA. Employing total internal reflection fluorescence microscopy (TIRFM), it was discovered that based on the length of the DNA, RPA associated with at least two binding modes: one that was defined at fast dissociating (Kd, 680 pM) and a slow dissociating (Kd, 60 pM) complex33,39. Given its pivotal involvement in nearly all DNA metabolic pathways, there has been a keen interest in creating inhibitors that can hinder the interaction between RPA and single-stranded DNA (ssDNA). These chemical inhibitors are vital in disrupting the DNA damage response, rendering cancer cells more susceptible to DNA-damaging agents employed in clinical therapies. Utilizing the BLI assay allows for a precise quantitative evaluation of inhibitor efficacy in modulating RPA's binding function40,41.
BLI setup allows for distinct settings: basic and advanced kinetics. In basic kinetics mode, the assay comprises three primary stages: baseline establishment, association, and dissociation. However, before performing this assay, the biosensors need to be coated separately, using either the instrument or manually on the laboratory bench. Conversely, the advanced kinetics mode extends beyond the fundamental three steps, allowing for the incorporation of additional steps. These supplementary steps can serve various purposes, such as conditioning the biosensor to the buffer alterations or facilitating the detection of subsequent protein interactions. Advanced kinetics also allows stripping the biosensor of the analyte by a good regeneration method for potential reuse, provided the bait and the biosensor remain intact. Generally, advanced kinetics is used over basic kinetics when multiple steps are involved in the assay, or the assay needs to be performed in a more complex format.
This protocol outlines both methods using the same bait [3'Bio-ss-poly (dT)32] and analyte (RPA). A streptavidin-coated biosensor will be used to immobilize the bait, and KD measurements for the analyte will be obtained. This protocol describes a complete approach to perform a BLI assay using a single-channel instrument biolayer interferometry, covering biosensor-bait preparation, buffer considerations, and a step-by-step outline of the procedure.